Emergent BioSolutions

Latest news

• FDA Approves Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
  20 July 2023
• Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
  24 June 2023
• NaxSwab OTC novel naloxone nasal swab successfully administered by children and adults to potentially rescue someone from an opioid overdose in study
  13 April 2023
• FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ Narcan Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
  29 March 2023
• New Drug Application for RiVive Over-the-Counter Naloxone Nasal Spray Accepted and Granted Priority Review by FDA
  26 December 2022
• Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter Narcan (naloxone HCl) Nasal Spray
  6 December 2022
• Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile
  30 July 2019
• Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile
  15 May 2019
• Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
  19 March 2019
• Narcan (naloxone HCl) Nasal Spray 2mg Approved by U.S. Food and Drug Administration
  25 January 2017

Drugs Associated with Emergent BioSolutions Inc.

Emergent BioSolutions Inc. manufactures, markets and/or distributes more than 10 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.